For decades, much of the pipeline of medical innovation has flowed from West to East. Now a string of companies are attempting to upend that trend with new drugs and products tailored to Asian bodies and lifestyles.
There is the Singapore-based drugmaker tackling an obscure cancer that is rare in the West, but common in Asia, where it has been linked to a popular fish dish.
Med-tech start-ups are preparing to sell tests to detect tumors more accurately in Asian women with denser breast tissue, including one wearable device that slips into a bra.
Photo: Reuters
Even big pharmaceutical firms like AstraZeneca and Roche Holding now have drugs targeting a lung cancer-causing mutation most often found in women from East Asia.
This simple yet radical departure comes as Asia’s booming economies and rising incomes enable higher spending on healthcare. That is providing incentive for more pharmaceutical companies to set up shop in the region, whether it is Western firms creating research and development centers to develop drugs for local populations, or new Asian drugmakers springing up.
Consultancy Frost & Sullivan predicts that total revenue for the Asian healthcare industry would jump 11 percent this year to US$517 billion.
Many of the researchers focusing on Asia have a simple starting point: Diseases and their cures can sometimes work differently in different populations, and a one-size-fits-all regimen tailored to the West is not sufficient.
The approach is cropping up most often in cancer care in Asia, home to tumors that are rare in the West.
“The patients are here, the tumor samples are here and also the basic know-how,” said Brigette Ma (馬碧如), a professor at the Chinese University of Hong Kong who specializes in new drug development. “By acknowledging diversity, not just in cultural and economic needs — by acknowledging diversity in terms of cancer care — we are getting the drugs to where they are needed.”
The shift is part of a broader trend sweeping through the global healthcare industry called precision medicine, which seeks to tailor treatment to a person’s specific genetic makeup and circumstances, including the ones commonly shared among people of the same ethnic group or culture.
In Asia, Japan has long been an important market for the healthcare industry and a site of new discoveries. However, the rapid growth of the rest of the region is heightening its importance as a whole and diversifying the industry’s focus in it.
Singapore-based biotech company Aslan Pharmaceuticals is now conducting late-stage human tests for a drug targeting bile duct and gastric cancers.
The prevalence throughout Asia of a stomach-infecting bacteria that can lead to cancer-causing inflammation is one factor that makes gastric cancer more common in the region.
However, research suggests it usually takes even more culturally specific traits, like the aggravating diet of salty and fermented foods common in northern China, Korea and Japan, to turn that inflammation cancerous.
Meanwhile, northeastern Thailand is the global center for an obscure disease called bile duct cancer. Rare in the West, researchers have traced its prevalence in certain parts of Southeast Asia to a fermented fish dish called koi pla beloved by the area’s Lao people. The cooking process for the dish often fails to kill an inflammation-causing parasite called the liver fluke and the infection can eventually lead to bile-duct cancer.
“There are very few effective treatment options for these patients,” Aslan chief executive officer Carl Firth said. “The focus was very much on cancers that were common in the West.”
Aslan has applied for so-called orphan drug status in the US and is seeking approval both there and in China. When it comes to patients in less affluent parts of Asia, such as bile-duct cancer patients in Thailand, Firth said his company could look for ways to help them access the drug after completing its clinical trials.
By controlling for both ethnicity and gender, researchers have over the past decade established that a particular cell mutation that causes lung cancer even in non-smokers is much more common in Asian women than anyone else.
This discovery has since opened the door for two multinational pharma companies, AstraZeneca and Roche, to develop and bring to market therapies that specifically target these parts of the cell, and so have proved to be particularly effective in Asian patients.
When it comes to breast cancer, just diagnosing it in the first place can be harder because research shows Asian women are more likely to have denser breasts than Caucasians.
That can obscure the tumor on a mammogram, leading doctors to miss it entirely or sometimes mistakenly identify one that is not there.
A host of start-ups have sprung up to tackle the problem.
In Singapore, a company called MiRXES plans to launch a test that will examine patients’ blood for microscopic particles that are byproducts of tumor growth, while another firm based in the city-state, Nova Satra Dx, has developed a test that checks chemical changes in how cells read their own DNA for signals they have turned cancerous.
Meanwhile, Reno, Nevada-based health tech start-up Cyrcadia Health has set up a unit in Hong Kong to launch a bra that picks up metabolic changes which may signal development of a tumor.
All these differences have led to postulation of an “Asian phenotype,” a distinctive way Asian people’s genes are expressed because of biology and environment.
Where traditionally the healthcare industry would seek approval for new products in the West before bringing them to Asia, now more firms are planning to go the other way for some diseases.
“These patients really need the drugs in Asia,” said Vishal Doshi, whose drug development start-up AUM Biosciences is focusing on therapies for Asia-prevalent cancers. “This is what I term an East to West philosophy, from a West to East philosophy.”
‘IN A DIFFERENT PLACE’: The envoy first visited Shanghai, where he attended a Chinese basketball playoff match, and is to meet top officials in Beijing tomorrow US Secretary of State Antony Blinken yesterday arrived in China on his second visit in a year as the US ramps up pressure on its rival over its support for Russia while also seeking to manage tensions with Beijing. The US diplomat tomorrow is to meet China’s top brass in Beijing, where he is also expected to plead for restraint as Taiwan inaugurates president-elect William Lai (賴清德), and to raise US concerns on Chinese trade practices. However, Blinken is also seeking to stabilize ties, with tensions between the world’s two largest economies easing since his previous visit in June last year. At the
UNSETTLING IMAGES: The scene took place in front of TV crews covering the Trump trial, with a CNN anchor calling it an ‘emotional and unbelievably disturbing moment’ A man who doused himself in an accelerant and set himself on fire outside the courthouse where former US president Donald Trump is on trial has died, police said yesterday. The New York City Police Department (NYPD) said the man was declared dead by staff at an area hospital. The man was in Collect Pond Park at about 1:30pm on Friday when he took out pamphlets espousing conspiracy theories, tossed them around, then doused himself in an accelerant and set himself on fire, officials and witnesses said. A large number of police officers were nearby when it happened. Some officers and bystanders rushed
Beijing is continuing to commit genocide and crimes against humanity against Uyghurs and other Muslim minorities in its western Xinjiang province, U.S. Secretary of State Antony Blinken said in a report published on Monday, ahead of his planned visit to China this week. The State Department’s annual human rights report, which documents abuses recorded all over the world during the previous calendar year, repeated language from previous years on the treatment of Muslims in Xinjiang, but the publication raises the issue ahead of delicate talks, including on the war in Ukraine and global trade, between the top U.S. diplomat and Chinese
RIVER TRAGEDY: Local fishers and residents helped rescue people after the vessel capsized, while motorbike taxis evacuated some of the injured At least 58 people going to a funeral died after their overloaded river boat capsized in the Central African Republic’s (CAR) capital, Bangui, the head of civil protection said on Saturday. “We were able to extract 58 lifeless bodies,” Thomas Djimasse told Radio Guira. “We don’t know the total number of people who are underwater. According to witnesses and videos on social media, the wooden boat was carrying more than 300 people — some standing and others perched on wooden structures — when it sank on the Mpoko River on Friday. The vessel was heading to the funeral of a village chief in